Join
Live feed
·
PRReleasevia Quantisnow
Dicerna Pharmaceuticals, Inc. logo

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

ByQuantisnow·Wall Street's wire, on your screen.
DRNA· Dicerna Pharmaceuticals, Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DRNA (Dicerna Pharmaceuticals, Inc.) and more on Quantisnow.